Anthony Nuara
Dermatology · Scottsdale, AZNPI 1912160482
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $341,602 of the $432,476 with a category attached, or 79.0%. 36 manufacturers reported payments, led by Dermavant Sciences, Inc. at 24.6% of the total. Among dermatology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,049 payments — averaging $412.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dermavant Sciences, Inc.$106K
- Amgen$102K
- E.r. Squibb & Sons, L.L.C.$66K
- Bristol Myers Squibb$38K
- Incyte Corporation$36K
- Novartis$34K
- plus $51K from 30 others
Across 133 payments — averaging $8227.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$851K
- AbbVie$149K
- Pfizer$56K
- Astrazeneca UK Limited$38K
What the payments were for
- Consulting fees$46,53011%
- Speaking & faculty fees$341,60279%
- Travel & lodging$16,8294%
- Food & beverage$27,1026%
- Education$4130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dermavant Sciences, Inc. | 94 | $106,262 |
| Amgen | 149 | $102,351 |
| E.r. Squibb & Sons, L.L.C. | 99 | $66,074 |
| Bristol Myers Squibb | 36 | $37,701 |
| Incyte Corporation | 72 | $35,640 |
| Novartis | 69 | $33,849 |
| Organon | 40 | $21,467 |
| Galderma Laboratories, L.p. | 31 | $7,024 |
| Johnson & Johnson | 60 | $5,163 |
| AbbVie(2 entities) | 118 | $4,521 |
| UCB, Inc. | 45 | $2,735 |
| Janssen Scientific Affairs, LLC | 4 | $2,029 |
| Arcutis Biotherapeutics, Inc. | 7 | $1,644 |
| Sun Pharmaceutical Industries Inc. | 51 | $1,149 |
| Lilly USA, LLC | 41 | $905 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 24 | $879 |
| Biofrontera Inc. | 8 | $713 |
| Sanofi | 22 | $707 |
| LEO Pharma Inc. | 24 | $353 |
| Regeneron Healthcare Solutions, Inc. | 9 | $273 |
| Pfizer | 15 | $246 |
| Botanix SB Inc | 9 | $241 |
| Argenx US, Inc. | 1 | $108 |
| Kyowa Kirin, Inc. | 3 | $64 |
| Boehringer Ingelheim | 2 | $55 |
| Prugen, Inc. Pharmaceuticals | 4 | $52 |
| Almirall LLC | 2 | $51 |
| DUSA Pharmaceuticals, Inc. | 2 | $50 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $37 |
| Revance Therapeutics, Inc. | 1 | $32 |
| Solta Medical, A Division Of Bausch Health US, LLC | 1 | $23 |
| Boston Scientific | 1 | $21 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $16 |
| Merck | 1 | $15 |
| EPI Health, LLC | 1 | $15 |
| Dermira, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$432,476 in reported general payments places this provider in the 95th percentile of 305 dermatology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 57 | $312,703 |
| Dupixent PenDupilumab | 30 | $150,802 |
| Humira PenAdalimumab | 13 | $90,734 |
| Clobetasol Propionate | 160 | $8,614 |
| Ketoconazole | 280 | $4,044 |
| Doxycycline Hyclate | 121 | $3,933 |
| Triamcinolone Acetonide | 248 | $3,276 |
| Metronidazole | 58 | $3,274 |
| Pimecrolimus | 20 | $2,327 |
| Dutasteride | 63 | $2,103 |
| Minoxidil | 110 | $1,863 |
| Fluocinonide | 25 | $1,708 |
| ValacyclovirValacyclovir Hcl | 48 | $1,637 |
| Mycophenolate Mofetil | 15 | $1,121 |
| Hydroxychloroquine Sulfate | 28 | $992 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $102,351 | $312,70357 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 305 dermatology providers in Arizona.
Other dermatology in Scottsdale
- Aaron MangoldScottsdale$171K
- Matthew LafferScottsdale$152K
- Jacqueline WatchmakerScottsdale$123K
- Kristine RomineScottsdale$45K
- Aleksandar SekulicScottsdale$28K
- Richard AveritteScottsdale$19K
- Michael LehrerScottsdale$15K
- Shelly FriedmanScottsdale$14K
- Hannah HillScottsdale$13K
- Lindsay AckermanPhoenix$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.